JP2019501145A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501145A5 JP2019501145A5 JP2018528650A JP2018528650A JP2019501145A5 JP 2019501145 A5 JP2019501145 A5 JP 2019501145A5 JP 2018528650 A JP2018528650 A JP 2018528650A JP 2018528650 A JP2018528650 A JP 2018528650A JP 2019501145 A5 JP2019501145 A5 JP 2019501145A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- checkpoint inhibitor
- fucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263228P | 2015-12-04 | 2015-12-04 | |
| US62/263,228 | 2015-12-04 | ||
| US201662308583P | 2016-03-15 | 2016-03-15 | |
| US62/308,583 | 2016-03-15 | ||
| US201662321857P | 2016-04-13 | 2016-04-13 | |
| US62/321,857 | 2016-04-13 | ||
| PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501145A JP2019501145A (ja) | 2019-01-17 |
| JP2019501145A5 true JP2019501145A5 (OSRAM) | 2020-01-16 |
| JP6906520B2 JP6906520B2 (ja) | 2021-07-21 |
Family
ID=58797961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528650A Active JP6906520B2 (ja) | 2015-12-04 | 2016-12-02 | チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353524A1 (OSRAM) |
| EP (1) | EP3383404A4 (OSRAM) |
| JP (1) | JP6906520B2 (OSRAM) |
| KR (1) | KR20180086233A (OSRAM) |
| CN (1) | CN108289903B (OSRAM) |
| AU (1) | AU2016362993A1 (OSRAM) |
| BR (1) | BR112018011261A2 (OSRAM) |
| CA (1) | CA3005997A1 (OSRAM) |
| EA (1) | EA201891340A1 (OSRAM) |
| IL (1) | IL259479B (OSRAM) |
| MX (1) | MX385283B (OSRAM) |
| SG (2) | SG11201804263PA (OSRAM) |
| WO (1) | WO2017096274A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019165A2 (en) | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| IL271012B2 (en) * | 2017-06-07 | 2023-12-01 | Seagen Inc | T cells with reduced surface fucosylation and methods for their preparation and use |
| WO2019075449A1 (en) * | 2017-10-13 | 2019-04-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| JP2022514299A (ja) * | 2018-12-19 | 2022-02-10 | シージェン インコーポレイテッド | 抗体の制御されたフコシル化 |
| WO2021034774A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN111973749B (zh) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | 一种抗肿瘤免疫治疗的药物组合物 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN113274502B (zh) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于特定型三阴乳腺癌免疫治疗的组合物 |
| US20240238318A1 (en) * | 2021-05-06 | 2024-07-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
| CN113413465B (zh) * | 2021-06-15 | 2022-06-03 | 北京大学 | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 |
| CN115466297B (zh) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | L-岩藻糖的应用以及动物饲料 |
| WO2024077106A2 (en) * | 2022-10-04 | 2024-04-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019165A2 (en) * | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
-
2016
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 EA EA201891340A patent/EA201891340A1/ru unknown
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/zh not_active Expired - Fee Related
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/ja active Active
- 2016-12-02 MX MX2018006674A patent/MX385283B/es unknown
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en not_active Ceased
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/ko not_active Withdrawn
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/pt not_active Application Discontinuation
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501145A5 (OSRAM) | ||
| Parvez et al. | PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment | |
| JP2018530554A5 (OSRAM) | ||
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2016540042A5 (OSRAM) | ||
| Vacchelli et al. | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications | |
| RU2019120400A (ru) | Композиции и способы, связанные с клеточными системами для проникновения в солидные опухоли | |
| JP2017506227A5 (OSRAM) | ||
| JP2019519499A5 (OSRAM) | ||
| JP2016187356A5 (OSRAM) | ||
| JP2017537620A5 (OSRAM) | ||
| Farhat et al. | Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2019501151A5 (OSRAM) | ||
| JP2019527706A5 (OSRAM) | ||
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2017530950A5 (OSRAM) | ||
| ME00425B (me) | Liječenje sa anti-vegf antitijelima | |
| JP2018508525A5 (OSRAM) | ||
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2018525358A5 (OSRAM) | ||
| JPWO2020027100A1 (ja) | 抗体−薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| Morganti et al. | Combinations using checkpoint blockade to overcome resistance | |
| JPWO2022270524A5 (OSRAM) |